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Abstract
Background: Determine TB-LAM is the first point-of-care test (POC) for HIV-associated tuberculosis (TB) and rapidly
identifies TB in those at high-risk for short-term mortality. While the relationship between urine-LAM and mortality
has been previously described, the outcomes of those undergoing urine-LAM testing have largely been assessed
during short follow-up periods within diagnostic accuracy studies. We therefore sought to assess the relationship
between baseline urine-LAM results and subsequent hospitalization and mortality under real-world conditions
among outpatients in the first year of ART.
Methods: Consecutive, HIV-positive adults with a CD4 count < 100 cells/uL presenting for ART initiation were
enrolled. TB diagnoses and outcomes (hospitalization, loss-to-follow and mortality) were recorded during the first
year following enrolment. Baseline urine samples were retrospectively tested using the urine-LAM POC assay.
Kaplan Meier survival curves were used to assess the cumulative probability of hospitalization or mortality in the
first year of follow-up, according to urine-LAM status. Cox regression analyses were performed to determine
independent predictors of hospitalization and mortality at three months and one year of follow-up.
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Results: 468 patients with a median CD4 count of 59 cells/uL were enrolled. There were 140 patients (29.9%) with
newly diagnosed TB in the first year of follow-up of which 79 (56.4%) were microbiologically-confirmed. A total of
18% (n = 84) required hospital admission and 12.2% (n = 57) died within a year of study entry. 38 out of 468 (8.1%)
patients retrospectively tested urine-LAM positive – including 19.0% of those with microbiologically-proven TB
diagnoses (n = 15/79) and 23.0% (n = 14/61) of those with clinical-only TB diagnoses; 9 of 38 (23.7%) of patients
retrospectively testing LAM positive were never diagnosed with TB under routine program conditions. Among all
patients (n = 468) in the first year of follow-up, a positive urine-LAM result was strongly associated with all-cause
hospitalization and mortality with a corresponding adjusted hazard ratio (aHR) of 3.7 (95%CI, 1.9–7.1) and 2.6 (95%,
1.2–5.7), respectively.
Conclusions: Systematic urine-LAM testing among ART-naïve HIV-positive outpatients with CD4 counts < 100 cells/
uL detected TB cases that were missed under routine programme conditions and was highly predictive for
subsequent hospitalization and mortality in the first year of ART.
Keywords: Tuberculosis, Lipoarabinomannan, Antiretroviral therapy, Outpatient, Mortality, Africa
Background
Tuberculosis (TB) remains the leading cause of death
among people living with HIV (PLHIV) [1], especially
during the initial months of antiretroviral therapy
(ART), and is a key driver of morbidity and mortality in
ART programmes [2]. Both prevalent and incident TB
cases are concentrated in patients accessing ART ser-
vices for the first time and during the initial months of
treatment [3–6].
The proportion of patients being diagnosed with TB at
enrolment in ART clinics has increased in recent years,
in part due to implementation of systematic, symptom-
based screening [1]. The World Health Organization
(WHO), recommends that all PLHIV be screened at
each clinical encounter for the presence of cough, fever,
weight loss or night sweats and that those with any one
symptom (of any duration) undergo further microbiologic
testing with either Xpert MTB/RIF or smear microscopy
where Xpert is unavailable [7]. However, PLHIV can often
have non-specific presentations and may not manifest typ-
ical TB symptoms. This is reflected in the diagnostic per-
formance of the WHO-symptom screening rule; while it
approaches 90% sensitivity in ART-naïve patients, it’s speci-
ficity among such individuals is only 28% [8]. Symptom
based-screening therefore still fails to detect more than 10%
of all individuals with HIV-associated TB prior to ART ini-
tiation and its poor specificity makes it challenging to deter-
mine who to prioritize for further TB investigations, as
systematic testing of all PLHIV screening positive in low-
resource settings may not be feasible. Delayed and missed
TB diagnoses prior to ART initiation are key barriers to re-
ducing HIV-associated TB mortality in ART programmes
and thus there is significant interest in developing improved
TB screening and testing strategies [9].
The Alere Determine TB-LAM assay (Abbott Diagnos-
tics, Lake Bluff, IL,USA; henceforth ‘urine-LAM’) is a
simple lateral-flow, point-of-care test that detects
mycobacterial lipoarabinomannan in urine samples [10].
While its overall diagnostic accuracy is limited (pooled
sensitivity 42%), it has moderate sensitivity (54%) in
those with advanced HIV disease (CD4 counts ≤100
cells/μL) [11]. Notably, several studies have demon-
strated the prognostic value of urine-LAM, including a
meta-analysis, which found a positive urine-LAM result
to be associated with a two-fold increased mortality at
two to three months, even after adjusting for additional
covariates, including CD4 cell count [12]. Furthermore,
two randomized trials in sub-Saharan Africa found that
the use of urine-LAM in addition to routine investiga-
tions was associated with a survival benefit in high-risk
inpatients with advanced HIV [13, 14]. However, the
predominance of studies to-date have evaluated short-
term outcomes among patients undergoing urine-LAM
testing, with only a few studies assessing the relationship
between urine-LAM status and clinical outcomes be-
yond three months [15–20]. We therefore evaluated the
prognostic value of systematic urine-LAM testing among
HIV outpatients with CD4 counts < 100 cells/μL who
were presenting to ART services for the first time and
for whom very complete clinical outcomes up to one
year of follow-up were available, including TB diagnoses,
hospitalization records, losses-to-follow-up, and death.
Methods
This was a sub-study from a prospective cohort of ART-
naïve adults in whom systematic cryptococcal antigen
(CrAg) screening was implemented [21]. For the parent
study, all newly diagnosed, consecutive HIV positive pa-
tients presenting for ART to 2 outpatient clinics in Cape
Town, South Africa between May 2011 and April 2014
patients were eligible if they were ≥ 18 years of age at the
time of enrollment, ART-naïve, had a CD4 cell count
≤100 cells/μL and no prior history of Cryptococcal
disease. This sub-study was restricted to those who did
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not have a known TB diagnosis at the time of study
entry. All participants had baseline blood and urine sam-
ples obtained and had data collected prospectively at
study enrollment and every three months for the first
year of ART using data collected from patient records,
telephone or home visits [21]. Fresh clinical samples
were tested for the presence of CrAg as described below
and any remaining volumes were stored at -80C until
further testing was performed.
Prospective data including routine clinic blood investiga-
tions, ART management, hospital admissions, TB diagnosis
(clinical, radiological, histological and microbiological), op-
portunistic infections and outcomes (death, hospitalization
and lost-to-follow up) were collected on all patients at
three-monthly intervals for their first year of care. As per
the local HIV guidelines at the time when the study was
undertaken, all patients were started on an efavirenz-based
ART regimen within two to four weeks following their first
clinic appointment, unless there was a specific clinical indi-
cation to do otherwise [22]. No clinical specimens were
routinely obtained during follow-up visits. The study was
approved by the Research and Ethics Committee of the
University of Cape Town and all patients provided written
informed consent in their primary language.
Laboratory procedures
All patients with a clinical suspicion of TB (fever, night
sweats, weight loss, cough at least two weeks duration)
had samples sent to the laboratory by the clinic staff.
The specific investigations that were ordered varied from
patient to patient and correlated with the local policy at
the time that the patient was enrolled in the clinic [22].
The large majority of specimens collected for mycobac-
teriology were sputum samples, however non-respiratory
samples, including cerebrospinal fluid, pleural fluid,
blood, urine and lymph node fine needle aspirates were
collected as clinically indicated. Investigations available
in the laboratory included: Xpert MTB/RIF assay (Ce-
pheid inc., Sunnyvale, CA, USA), smear florescence
microscopy and automated liquid culture using myco-
bacterial growth indicator tubes (MGIT 960, Becton
Dickinson, Sparks, Maryland, USA). Frozen urine speci-
mens collected prior to ART initiation were thawed and
tested retrospectively in May 2014 for the presence of
lipoarabinnomannan (LAM) using the Determine TB-
LAM assay per manufacturer instructions; only 17
(3.6%) of samples that were urine CrAg positive had pre-
viously undergone a freeze-thaw cycle to determine
CrAg titres. Three of the four trained personnel (NK,
NL, MV, SDL) read the results for each specimen inde-
pendently and a majority consensus was reached. A
positive LAM result was defined using grade 2 cut-off
on the old manufacturer’s card as this was the basis of
expert opinion and WHO guidelines at the time [23];
this corresponds with a grade 1 cut-off using the current
manufacturer’s card. Baseline serum, plasma, urine,
whole blood and CSF (where available) were tested pro-
spectively for CrAg using a lateral flow assay (LFA)
(IMMY, Oklahoma, USA) and those screening positive
had CrAg titres determined using the CrAg LFA-IMMY
kit, as previously described [21].
TB-related definitions
‘Newly diagnosed TB’ was defined as any patient with a
new TB diagnosis at any point between study entry and
up to one year after enrolment, independent of whether
the diagnosis was based on microbiological, clinical or
radiological evidence. The term ‘incident TB’ was
intentionally not utilized, as patients were not system-
atically tested for active TB at study entry and thus
new diagnoses during ART could reflect either preva-
lent TB disease that was missed at study entry or inci-
dent disease that developed while taking ART. A
‘microbiological TB diagnosis’ was defined by the de-
tection of M. tuberculosis by Xpert MTB/RIF or cul-
ture on any clinical sample; notably, the detection of
acid-fast bacilli (AFB) by sputum microscopy was not
considered a microbiologically-confirmed TB case
unless TB was also detected by culture or Xpert. A
“clinical TB diagnosis” was defined as any patient who
was started on TB therapy without the presence of a
positive Xpert or culture result.
Outcomes of interest
In addition to data gathered during follow up visits,
dates of TB diagnoses and TB therapy (if applicable) as
well as clinical outcomes (hospitalization, mortality)
were also collected from the National Health Laboratory
Service (NHLS) electronic results database, the Depart-
ment of Home Affairs Death Register and the provincial
Government electronic database systems (eKapa and
Tier.net). All patients who missed one of their three-
monthly clinic visits were traced by study staff using
telephone calls and home visits. Any patient whom
could not be confirmed as either alive or dead at one
year of follow-up using any of the above sources of
information was defined as ‘LTFU.'
A ‘composite adverse outcome,’ was defined as any pa-
tient who required hospitalization for any reason (all-
cause), was LTFU and/or died (all-cause) within one
year of ART initiation (or one year after study entry for
the small proportion who did not start ART). For the
purposes of evaluating the relationship between urine-
LAM status and outcomes, we categorized patients into
one of three mutually-exclusive groups: urine-LAM posi-
tive, urine-LAM negative/TB diagnosed in the first year
of follow-up, or urine-LAM negative/no TB diagnosed
in the first year of follow-up.
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Statistical analysis
Data were analysed using Stata version 14.0 (Stata-
Corp, College Station, Texas, USA). Proportions and
medians were compared using either Pearson’s chi-
squared, Fisher’s exact and Wilcoxon rank-sum tests as ap-
propriate. Cox regression analysis was performed to evalu-
ate the association between urine-LAM positivity and
hospitalization as well as mortality at three months and
one year of follow-up. Person-time was accrued from
the date of study enrolment until death, lost-to-follow-
up, first hospitalization (in hospitalization-related ana-
lyses) or censorship 365 days after study enrolment. Di-
rected acyclic graphs (DAG) were used to identify
confounders of the relationship between urine-LAM
and hospitalization and urine-LAM and mortality [24];
therefore, a priori covariates for both hospitalization and
mortality were age, hemoglobin level, and CD4 count
based on the minimal sufficient adjustment sets. It is not
known whether sex may be causally associated with urine-
LAM status; given such uncertainty, a change in estimate
approach was utilized and sex was only included if the
adjusted urine-LAM point estimate differed by > 10%, so
as to not reduce statistical precision. Schoenfeld’s global
test was used to test the proportional hazards assumption.
Kaplan Meier survival curves were made to visualize the
cumulative incidence and timing of TB treatment
initiation as well as the cumulative incidence of adverse
clinical outcomes (hospitalization or mortality) in the first
year of follow-up, according to urine-LAM status.
Results
Patient characteristics
Six hundred seventy patients were identified for possible
inclusion in the parent study of whom 468 met inclusion
Fig. 1 Flow diagram showing the study population, the number of patients included as well as urine-LAM results, adverse outcomes, and TB
diagnoses within one year of ART initiation. Hospitalizations and deaths were not mutually exclusive, such that some patients were
hospitalized and subsequently died. Therefore, the total number of patients with newly diagnosed TB was 140 and the total number of patients
with a positive urine-LAM result was 38
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criteria and had complete results available for this sub-
study (Fig. 1). Among the 202 patients excluded, 105
had a known TB diagnosis and were receiving TB treat-
ment at the time of study entry, of which 41 (40.0%)
retrospectively tested urine-LAM positive.
Patients included in the study (n = 468) were young
(median 35 years old) and the majority were women
(55%). They had advanced immunosuppression (median
CD4 59 cells/μL) and tended to be anemic (Table 1).
More than 90% of all patients started ART, with a me-
dian time to ART initiation of 15 days (IQR, 11–26).
Baseline characteristics did not differ between the two
study sites and thus data from two sites were combined
for all subsequent analyses (data not shown).
Overall TB diagnoses
There were 140 patients with a TB diagnosis made (ei-
ther microbiological or clinical) within the first year of
study entry for a combined prevalence and incidence of
29.9% (95%, 26.0–34.3); however, only 79 (56.4%) of
such patients had a microbiologically-proven diagnosis
by either Xpert or culture.
TB diagnosis characteristics stratified according to urine-
LAM assay result
Overall, 38/468 (8.1%) patients retrospectively tested
urine-LAM positive (Table 2), of which three-quarters
(76.3%; n = 29/38) were prospectively diagnosed with TB
(either microbiological or clinical) within one year of en-
rolment. Among those with microbiologically-proven TB
(n = 79) and a clinical-only TB diagnosis (n = 61), urine-
LAM retrospectively detected TB in 15 (19.0%) and 14
(23.0%) patients, respectively. Urine-LAM positive pa-
tients were less likely to have microbiologically-proven
TB compared to patients diagnosed with TB, testing
urine-LAM negative (39.5% vs. 57.7%; p = 0.05) (Table
2). Notably, patients who retrospectively tested urine-
LAM positive were substantially less likely to have had a
clinical specimen undergo Xpert or culture-based testing
for TB in the first year of follow-up (47.4% vs. 81.1%,
p < 0.001, supplementary Table 1).
Of patients prospectively diagnosed with TB in the
first year of ART (n = 140), those who tested urine-
LAM positive had earlier TB diagnoses compared
those who tested urine-LAM negative (5 days vs. 16
days, p = 0.005); the timing of TB diagnoses did not
differ substantially between those who had a micro-
biological diagnosis vs. a clinical-only diagnosis (Table
2). Among urine-LAM positive patients who were
prospectively diagnosed with TB, 7 (24.1%) were diag-
nosed more than 14 days after study entry (maximum
186 days).
9 of 38 (23.7%) patients found to be urine-LAM
positive at study entry did not have a TB diagnosis
(clinical or microbiological) made under routine pro-
gram conditions at any time point in the first year
following study enrolment (supplementary Table 2).
Their median CD4 count was 75 cells/μL (IQR, 24–
80) and median hemoglobin concentration was 10.5 g/
dL (IQR, 8.0–12.7). Five of the 9 patients were LAM
grade 3 positive or greater, strongly suggesting a true
positive result, including one of whom died less than
10 days after study enrolment. An additional patient
died within two weeks of enrolment after subsequently
presenting to the hospital with sepsis physiology. The
remaining 3 of 9 urine-LAM positive patients without
a TB diagnosis were never hospitalized and remained
alive at one year after study entry without known re-
ceipt of anti-TB therapy, suggesting the possibility of a false
positive result, although it should be considered that these
patients did experience immune reconstitution in the set-
ting of ART initiation. No patients were diagnosed with
non-tuberculous Mycobacterial infection, Cryptococcus, or
other opportunistic infections; while patients were system-
atically screened for the presence of Cryptococcal
infection at study entry, they were not systematically
investigated for non-tuberculous mycobacteria or
other opportunistic infections.
TB treatment characteristics stratified according to urine-
LAM assay result
Among the 140 patients with a new TB diagnosis in the
first year of follow-up, 134 (95.7%) were subsequently
started on anti-TB therapy (Table 2). Notably, less than
two-thirds of patients retrospectively testing urine-LAM
Table 1 Baseline characteristics among patients not on
tuberculosis therapy at study entry (n = 468)
All patients
(n = 468)
Age, median (IQR) 35.4 (30.2–40.8)
Sex
Male 209 (44.7)
Female 259 (55.3)
CD4 cell count (cells/μL)
Median (IQR) 59 (32–80)
< 50 193 (41.2)
50–99 275 (58.8)
Hemoglobin (g/dL)a
Median (IQR) 11.0 (9.3–12.5)
Anemia severity
Moderate/severe 209 (47.2)
None/mild 234 (52.8)
Creatinine (μmol/L)b 68 (58–83)
Abbreviations: IQR interquartile range
an = 443; bn = 425
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positive were started on TB therapy compared to nearly
all (98.2%) of those with a urine-LAM negative TB diag-
nosis (Table 2). In addition to the 9 patients who were
not diagnosed with TB in the first year of follow-up (and
therefore were not started on TB treatment), there were
4 patients who were urine-LAM positive and diagnosed
Table 2 Diagnosis and treatment outcomes by baseline LAM status among patients not on anti-TB treatment at study entry (n = 468)
All patients
(n = 468)
LAM positive
(n = 38)
LAM Negative/
TB diagnosis
(n = 111)
LAM Negative/No
TB diagnosis
(n = 319)
P-value*
Tuberculosis diagnoses within one year of ART
TB diagnosis (microbiological or clinical)
Yes 140 (29.9) 29 (76.3) 111 (100) 0 < 0.001
No 328 (70.1) 9 (23.7) 0 319 (100)
Time to TB diagnosis (median [IQR] in days;
microbiological or clinical)a
14 (2–36) 5 (0–13) 16 (3–45) – 0.005
TB diagnosis (microbiologically-proven only)
Yes 79 (16.9) 15 (39.5) 64 (57.7) 0 0.053
No 389 (83.1) 23 (60.5) 47 (42.3) 319 (100)
Time to TB diagnosis (median [IQR] in days;
microbiologically-proven only)b
15 (3–36) 5 (2–13) 21 (3–41) – 0.025
TB diagnosis (clinical only)
Yes 61 (13.0) 14 (36.8) 47 (42.3) 0 0.55
No 407 (87.0) 24 (63.2) 64 (57.7) 319 (100)
Time to TB diagnosis (median [IQR] in days;
clinical only)c
14 (0–36) 4 (0–18) 15 (1–70) – 0.10
TB and HIV treatment
Started TB treatment (within one year of study entry among all patients)
Yes# 134 (28.6) 25 (65.8) 109 (98.2) 0 < 0.001
No 334 (71.6) 13 (34.2) 2 (1.8) 319 (100)
Time to initiation of TB treatment (median
[IQR] in days)d
17 (5–42) 7 (1–14) 23 (7–51) – 0.001
TB treatment outcomes (among those starting within one year of study entry)d
Completed 94 (70.7) 16 (64.0) 78 (72.2) – 0.53
Did not complete 9 (6.8) 1 (4.0) 8 (7.4) –
Died on therapy 19 (14.3) 6 (24.0) 13 (12.0)
Unknown 11 (8.3) 2 (8.0) 9 (8.3) –
Started ART (within one year of study entry)e
Yes 430 (91.9) 27 (71.1) 105 (94.6) 298 (93.4) < 0.001
No 38 (8.1) 11 (29.0) 6 (5.4) 21 (6.6)
Time to initiation of ART (median
[IQR] in days)e
15 (11–25) 23 (14–32) 21 (14–35) 14 (9–22) < 0.001
ART status within one year of study entry (among those who started)e
On ART, no switch, did not default 344 (80.0) 22 (81.5) 85 (81.0) 237 (79.5) 0.95
On ART, switched 32 (7.4) 3 (11.1) 8 (7.6) 21 (7.1)
Off ART, defaulted 50 (11.6) 2 (7.4) 11 (10.5) 37 (12.4)
Unknown 4 (0.9) 0 1 (1.0) 3 (1.0)
*In analyses restricted to among patients with microbiologically-confirmed TB (n = 79), p-values reference the comparison between LAM positive patients and LAM
negative, TB-positive patients only
Abbreviations: ART antiretroviral therapy, TB tuberculosis
an = 140; bn = 79;cn = 61;dn = 133en = 430
#6 patients with a TB diagnosis within one year of study entry were not known to have started TB therapy, 3 patients had unknown TB treatment status (1 LAM
positive), 3 patients died prior to starting TB therapy (3 LAM positive)
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with TB, but were not known to have started TB treat-
ment (supplementary Table 2). Three of 4 patients died
prior to receiving TB treatment, while the fourth was
not known to have started TB treatment but was alive at
one year of follow-up. Among patients who were started
on TB treatment (n = 134), the proportion who com-
pleted TB therapy did not differ by urine-LAM result
(64.0% vs. 72.2%, p = 0.53; Table 2). Patients testing
urine-LAM positive were also less likely to have been
initiated on ART compared to those testing urine-LAM
negative (71.1% vs. 94.6%, p < 0.002; Table 2); however,
among those who started ART, ART-status at one year
did not differ according to the urine-LAM result (Table
2).
Of patients starting TB treatment (n = 134), the me-
dian time to initiation of treatment was 17 days (IQR, 5–
42). While patients who retrospectively tested urine-
LAM positive were substantially less likely to have been
started on TB treatment, those starting TB treatment
were more rapidly initiated on treatment compared to
patients who tested urine-LAM negative (7 days vs. 23
days, p < 0.001; Table 2; Fig. 2).
Overall outcomes
Overall, 116 (24.8%) of patients had at least one ad-
verse outcome within one year of study entry (‘com-
posite adverse outcome’). This comprised 84 (17.3%)
persons who required hospitalization, 57 (12.2%) who
died, and 7 (1.5%) who were LTFU (Fig. 1). Among
all patients, the median time to hospitalization was
39 days (IQR, 13–129), while the median time to
death was 74 days (IQR, 25–140).
Relationship between urine-LAM result and all-cause
hospitalization in the first year of follow-up
We evaluated the relationship between urine-LAM re-
sult and TB diagnosis (either microbiological or clinical)
in the first year of enrolment with the patient’s clinical
outcomes (Table 3). Overall, urine-LAM positive pa-
tients had poorer outcomes and tended to experience
them sooner after study entry, compared to those who
tested urine-LAM negative (either with or without a TB
diagnosis) (Table 3). Nearly one-third and one-half of
patients retrospectively testing urine-LAM positive re-
quired hospitalization within three months and one year
following study entry, respectively; this was a signifi-
cantly larger proportion than either urine-LAM nega-
tive/TB-positive patients or urine-LAM negative/ TB-
negative patients (Table 3; Fig. 3a). Urine-LAM positive
patients accounted for more than 20% (n = 17/84) of all-
cause hospitalization within the first year of study enrol-
ment in this cohort (Table 3).
A positive urine-LAM result was strongly associated
with 90-day (adjusted hazard ratio = [aHR] = 3.1) and
one year all-cause hospitalization (aHR = 3.7) (Table 4);
TB patients who tested urine-LAM negative had lower
hospitalization rates compared to urine-LAM positive
patients (aHR = 2.0 and 2.4 at 90 days and one year, re-
spectively), but such patients were still more likely to be
hospitalized than patients without a TB diagnosis (Table 4).
When the analysis was restricted to among those with a
microbiologically-confirmed diagnosis of TB (n = 79), a
positive urine-LAM result was associated with a higher
cumulative incidence of hospitalization in the first year of
follow-up compared to those testing urine-LAM negative
(Fig. 3b); in such patients a positive urine-LAM result did
Fig. 2 Cumulative probability of starting tuberculosis treatment within one year of study entry according to urine-LAM result (n = 149)
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not, however, independently predict need for subsequent
hospitalization (Table 4).
Relationship between urine-LAM result and all-cause
mortality in the first year of follow-up
Nearly one-third (n = 12, 31.6%) of patients retrospect-
ively testing urine-LAM positive died within a year of
enrolment; this was compared to 15.3% (n = 17) of pa-
tients who were urine-LAM negative, but had TB diag-
nosis within a year of study enrolment and 8.8% (n = 28)
among those without a TB diagnosis in the first year of
follow-up (p = 0.002; Table 3; Fig. 4a). Patients testing
urine-LAM positive accounted for 36% (n = 11/31) of all
deaths occurring within 90 days and 21% (n = 12/57) of
all deaths occurring during the first year. Notably, 5 of
13 (38.5%) urine-LAM positive patients who were never
started on TB treatment died in the first year of follow-
up, of which 4 died more than a week after study entry
(supplementary Table 2). There were 25 urine-LAM
positive patients who were prospectively diagnosed with
TB and started on TB treatment; of the 6 patients
started on TB treatment within 72 h of study entry, only
1 died (16.7%), compared to 6 (31.6%) of 19 patients
who died after being started on TB treatment more than
72 h after study entry.
In multivariable analyses, a positive urine-LAM result
was strongly associated with an increased hazard of mortal-
ity at 90 days (aHR = 3.8) and one year (aHR = 2.6; Table
4). Among those with microbiologically-confirmed TB (n =
79), a positive urine-LAM result was associated with a
higher cumulative mortality incidence compared to those
with a negative urine-LAM result (Fig. 4b) and there was a
trend towards an increased hazard of death at 90 days and
one year (Table 4).
Discussion
This study found that among ambulatory, HIV positive
outpatients with severe baseline immunosuppression
(CD4 < 100 cells/μL) in the first year of ART, nearly
one-third had a new TB diagnosis (prevalent or incident
Table 3 Outcomes by baseline urine-LAM status among patients not on anti-TB treatment at study entry (n = 468)
All patients
(n = 468)
LAM positive
(n = 38)
LAM Negative/
TB diagnosed
(n = 111)
LAM Negative/
No TB diagnosed
(n = 319)
p-value
Clinical outcome at threemonths
Required hospitalization 50 (10.7) 10 (26.3) 20 (18.0) 20 (6.3) < 0.001
Hospital readmission 4 (0.9) 0 2 (1.8) 2 (0.6) 0.48
Vital status
Dead 31 (6.6) 11 (29.0) 6 (5.4) 14 (4.4) < 0.001
LTFU 2 (0.4) 0 0 2 (0.6)
Alive 435 (93.0) 27 (71.1) 105 (94.6) 303 (95.0)
Clinical outcome at six months
Required hospitalization 73 (15.6) 16 (42.1) 29 (26.1) 28 (8.8) < 0.001
Hospital readmission 6 (1.3) 1 (2.6) 3 (2.7) 2 (0.6) 0.14
Vital status
Dead 44 (9.4) 12 (31.6) 11 (9.9) 21 (6.6) < 0.001
LTFU 2 (0.4) 0 0 2 (0.6)
Alive 422 (90.2) 26 (68.4) 100 (90.1) 296 (92.8)
Clinical outcome at one year
Required hospitalization 84 (18.0) 17 (44.7) 36 (32.4) 31 (9.7) < 0.001
Median time to hospitalization (IQR), (median [IQR] in days)a 39 (13–129) 18 (4–118) 74 (14–166) 31 (14–149) 0.39
Hospital readmission 10 (2.1) 1 (2.6) 5 (4.5) 4 (1.3) 0.10
Vital status
Dead 57 (12.2) 12 (31.6) 17 (15.3) 28 (8.8) 0.002
LTFU 7 (1.5) 0 1 (0.9) 6 (1.9)
Alive 404 (86.3) 26 (68.4) 93 (83.8) 285 (89.3)
Median time to death (IQR), (median [IQR] in days)b 74 (25–140) 19 (8–65) 124 (38–259) 90 (27–160) 0.002
Died without starting TB treatment (among all patients) 35 (7.5) 5 (13.2) 2 (1.8) 28 (8.8) 0.021
Abbreviations: LTFU lost-to-follow-up
an = 84; bn = 57
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TB) and one-quarter had at least one adverse outcome,
including need for hospitalization, LTFU, or death. A
positive urine-LAM result prior to ART initiation (tested
retrospectively) was strongly and independently associ-
ated with the need for hospitalization as well as mortal-
ity during the first year of follow-up. These results add
to prior studies demonstrating the prognostic value of
urine-LAM testing among HIV-positive outpatients with
advanced immunodeficiency [16–20, 25].
This was a pragmatic study undertaken in real-world
clinical conditions without systematic TB testing at base-
line and allowed us to determine that approximately
one-quarter of patients who retrospectively tested LAM
positive were never diagnosed with TB and more than
one-third were never started on anti-TB therapy. Nearly
half of all patients testing urine-LAM positive ultimately
required hospitalization in the first year of ART. Fur-
thermore, 12 patients testing urine-LAM positive prior
to ART initiation died within a year of enrolment; 5 died
without being started on TB treatment (4 of which died
more than one week after study entry), while an add-
itional 6 died among those who had delayed initiation of
TB treatment (> 72 h after study entry). Ultimately, pa-
tients testing urine-LAM positive accounted for 35% and
21% of all-cause deaths occurring within 90 days and
one year of enrolment, respectively, despite accounting
for just 8% of the overall study population.
Previous studies among both inpatients and outpa-
tients have shown urine-LAM to be an independent pre-
dictor of poor clinical characteristics, including early
mortality [12, 26]. In the present study, we found that a
positive urine-LAM result prior to ART initiation was a
Fig. 3 Cumulative probability of hospital admission within one year of study entry according to urine-LAM and tuberculosis diagnosis category
among a) all patients (n = 468), b) patients with with new microbiological TB diagnosis in the first year of study entry (n = 79)
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strong predictor of the need for hospitalization as well
as subsequent mortality in the first year following ART
initiation. This is consistent with prior observational
outpatient studies that have also found that a positive
urine-LAM result predicts six-month and one-year mor-
tality during ART [16–20, 25]. However, in each of these
studies, including the present study, mortality in those
who tested urine-LAM positive was largely restricted to
within three months of ART initiation. The association
between positive urine-LAM testing and an increased
risk of mortality in these studies likely reflects high
mycobacterial burden and disseminated TB in the con-
text of advanced HIV-associated immunodeficiency [27,
28]. While many urine-LAM positive patients may have
direct renal involvement with TB, especially those with
advanced HIV [29], there is increasing evidence that
LAM antigeneuria might also reflect glomerular filtration
of systemically circulating LAM (or LAM components)
[30, 31].
Based on an updated appraisal of the literature [11],
WHO guidelines have been recently revised to now
recommend urine-LAM testing be considered among
PLHIV presenting to outpatient settings with 1) signs
and symptoms of TB and/or who are seriously ill, and 2)
in those who have CD4 counts < 100 cells/μL, irrespect-
ive of TB signs and symptoms [32]. Despite initial WHO
recommendations for urine-LAM testing for the evalu-
ation of HIV-associated TB being made in 2015, only a
small number of high-burden countries have incorpo-
rated urine-LAM testing into the TB diagnostic
Table 4 Cox regression analyses for hospitalization and mortality in the first year of ART according to urine-LAM result and TB
diagnosis category among ART-naïve adults
Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) P-value
Hospitalization at 90 days
No TB diagnosed 1.0 < 0.001 1.0 0.025
Urine-LAM negative/TB diagnosed 2.88 (1.55–5.35) 1.97 (1.02–3.81)
Urine-LAM positive 5.36 (2.51–11.46) 3.09 (1.33–7.17)
Hospitalization at one year
No TB diagnosed 1.0 < 0.001 1.0 < 0.001
Urine-LAM negative/TB diagnosed 3.35 (2.07–5.41) 2.42 (1.45–4.06)
Urine-LAM positive 5.95 (3.29–10.58) 3.65 (1.89–7.06)
Hospitalization at 90 days among those with microbiologically-confirmed TB (n = 79)
Urine-LAM negative 1.0 0.07 1.0 0.29
Urine-LAM positive 2.44 (1.00–5.93) 1.75 (0.64–4.78)
Hospitalization at one year among those with microbiologically-confirmed TB (n = 79)
Urine-LAM negative 1.0 0.019 1.0 0.16
Urine-LAM positive 2.49 (1.22–5.06) 1.84 (0.80–4.27)
Mortality at 90 days
No TB diagnosed 1.0 < 0.001 1.0 0.015
Urine-LAM negative/TB diagnosed 1.23 (0.47–3.20) 1.01 (0.37–2.74)
Urine-LAM positive 7.67 (3.48–16.90) 3.83 (1.52–9.66)
Mortality at one year
No TB diagnosed 1.0 1.0 0.07
Urine-LAM negative/TB diagnosed 1 1.40 (0.74–2.67)
Urine-LAM positive 2.60 (1.19–5.66)
Mortality at 90 days among those with microbiologically-confirmed TB (n = 79)
Urine-LAM negative 1.0 0.016 1.0 0.07
Urine-LAM positive 4.95 (1.43–17.12) 3.90 (0.91–16.72)
Mortality at one year among those with microbiologically-confirmed TB (n = 79)
Urine-LAM negative 1.0 0.035 1.0 0.10
Urine-LAM positive 3.23 (1.17–8.90) 2.84 (0.86–9.41)
All analyses among n = 468 patients unless explicitly stated otherwise
P-value based on likelihood-ratio test
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algorithm [33, 34]. Even where urine-LAM testing has
been implemented, it is rarely utilized among outpa-
tients. Diagnostic studies among ART-naïve outpatients
have previously found that urine-LAM’s use increased
diagnostic yield [20, 35, 36]. However, when urine-LAM
was evaluated among more immunocompetent ambula-
tory patients, including those who are ART-experienced
[18] and in the setting of community case finding studies
[37], its additive yield was marginal.
While urine-LAM may increase overall TB diagnostic
yield, its greatest clinical utility lies in its ability to rap-
idly detect TB in less than 30min in PLHIV who are at
greatest risk for morbidity and mortality [33]. Among
outpatients, urine-LAM is likely to have greatest impact
in settings where same-day evaluations and diagnostics
(chest X-ray, sputum microscopy and sputum Xpert) are
not available, as its use would allow for immediate
same-day initiation of potentially lifesaving therapy [20];
however, the TB FAST-TRACK study found that urine-
LAM testing as part of a point-of-care TB algorithm to
enable nurses at primary health-care clinics to initiate
empirical TB was associated with increased TB treatment
coverage, but did not reduce mortality [38]. The reasons
underpinning a lack of mortality benefit associated are not
fully clear, but TB FAST-TRACK investigators concluded
that the development and implementation of more sensi-
tive, point-of-care TB tests that could be feasibly utilized
at primary health-care clinics should be prioritized.
Fig. 4 Cumulative probability of mortality according to urine-LAM and tuberculosis diagnosis category among a) all patients (n = 468), b) patients
with new microbiological TB diagnosis in the first year of study entry (n = 79)
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Strengths of this study include that patients were con-
secutively recruited from two different clinic sites, data
were prospectively collected up to one year after ART
initiation and the study took place under real-world pro-
grammatic conditions. Additionally, clinical outcomes at
one year were very complete (LTFU was approximately
1.5%) as a result of ascertainment through phone and
in-person tracing by study staff as well through extrac-
tion from multiple electronic databases. There were
however, some weaknesses. The WHO symptom screen
was not systematically recorded at baseline as the WHO
recommendation (and subsequent roll-out) followed the
study’s design. Routine microbiological testing for TB
using either Xpert and/or culture was not undertaken as
in our previous studies, which did not allow for a refer-
ence standard to determine the diagnostic accuracy of
the urine-LAM assay or calculation of the true TB
prevalence in this patient population. Additionally, be-
cause systematic TB testing was not undertaken, 9
urine-LAM positive patients were without a microbio-
logical TB diagnosis and we cannot exclude the possibil-
ity of a false positive result in some of these patients.
We overall believe that only a small proportion (3 or
less) may have represented a false positive result, given
that the majority had a strongly positive urine-LAM re-
sult, coupled with data from our previous studies in this
setting that have demonstrated among both ambulatory
and hospitalized patients that the specificity of LAM ex-
ceeds 98% when a robust reference standard is utilized
[39, 40]. Finally, the apparent yield of urine-LAM in this
cohort was lower than might be expected among
patients with advanced immunodeficiency given prior
evaluations [11]. We believe that this reflect a number of
factors, including: 1) a large proportion of patients di-
agnosed with TB prior to referral for ART initiation
and therefore not included in the study - potentially
underestimating urine-LAM’s utility in this setting (as
evidenced by the finding that approximately 40% of pa-
tients excluded due to a known TB diagnosis at study
entry were urine-LAM positive), 2) a lack of systematic
microbiological investigations for TB prior to ART ini-
tiation (including a lower frequency of culture and
Xpert testing among urine-LAM positive patients), and
3) systematic urine-LAM testing undertaken among all
patients regardless of symptoms (likely lowering the
pre-test probability and overall TB prevalence).
Conclusion
Systematic testing for HIV-associated TB using the
urine-LAM point-of-care assay prior to ART initiation
was highly predictive for hospitalization and mortality in
the first year of ART. Urine-LAM testing among ambu-
latory adults with CD4 cell counts < 100 cells/μL may
help to avert preventable TB-related mortality.
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